Status:
TERMINATED
A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
Obstetric Labour, Premature
Premature Ejaculation
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
PreTerm Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the ...
Eligibility Criteria
Inclusion
- Healthy males and non-pregnant female
- Between the ages of 18 and 50 years old.
- Females may be of child-bearing or non-child-bearing potential.
- Non-smokers
- BMI of between 19 and 30 kg/m2 (weight of greater than 110lbs).
Exclusion
- History of smoking within past 6 months
- Regular alcohol consumption averaging 7 drinks or more per week
- Subject is positive for hepatitis C antibody, hepatitis B surface antigen, or HIV
- Use of prescription or non-prescription drugs within 14 days of study start
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00449709
Start Date
March 1 2007
Last Update
March 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Tacoma, Washington, United States, 98418